Please login to the form below
myeloma
This page shows the latest myeloma news and features for those working in and with pharma, biotech and healthcare.
BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment
An estimated 35, 000 new cases of multiple myeloma will be diagnosed in the US this year. ... Multiple myeloma is a blood cancer that impacts plasma cells – a type of white blood cell – which are found in the bone marrow.
Latest news
-
Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
R multiple myeloma.
-
Kite and Arcellx close multiple myeloma collaboration agreement
Kite, a Gilead Company, and Arcellx have announced the closing of their collaboration agreement to jointly develop and commercialise Arcellx’s late-stage candidate to treat relapsed or refractory multiple myeloma. ... As the third most common
-
Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE
adult patients with relapsed or refractory multiple myeloma (RRMM) who have received two or three lines of therapy, the company announced. ... Multiple myeloma is a life-threatening rare blood cancer affecting plasma cells found in bone marrow.
-
Kite and Arcellx partner to develop and commercialise multiple myeloma candidate
late-stage product candidate, CART-ddBCMA, for patients with relapsed or refractory multiple myeloma (MM).
-
Pfizer shares updated pivotal phase 2 elranatamab data for multiple myeloma
Elranatamab is an investigational, humanised B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), which targets both BCMA-expressing multiple myeloma cells and CD3-expressing T-cells, binding both and ... Multiple myeloma is a blood
More from news
Approximately 102 fully matching, plus 267 partially matching documents found.
Latest Intelligence
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Finally, in multiple myeloma, a first-in-class bispecific T-cell engager antibody – talquetamab – is showing promise in heavily pre-treated patients.
-
ASH 2022: bad blood but big advances
Special interest sessions during the ASH-FDA Joint Symposium picked out advances in disease states as diverse as multiple myeloma, B-cell lymphoma and AML, while in non-malignant haematology it ... Multiple myeloma was a major focus, with data
-
CAR-T cell therapy in oncology
To date, all are approved for the treatment of blood cancers, including lymphomas, leukaemias, and, most recently, multiple myeloma.
-
Successful product commercialisation: what can we learn from the rare disease setting?
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical
-
Evolution or revolution: the latest review of NICE methods
It was also only in June that the results of a study, with £120, 000 funding from Myeloma UK, reported on measuring patient preferences and explored how to determine how patient
More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.
Latest appointments
-
Paolo Paoletti named as executive chairman of Kesios
interesting pre-clinical science in an impactful medicine for patients affected by multiple myeloma and other forms of cancer.”.
-
Celgene names general manager for UK and Ireland
This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
What does the future hold for Light-chain Amyloidosis?
Physicians we’ve asked, report the kidneys and heart are the most commonly involved organs and that just over a third of patients also have multiple myeloma. ... In the absence of approved therapies, the treatment strategy being adopted was very much
-
If our patients are diverse, why are clinical trials so white?
Ninlaro is an oral treatment for multiple myeloma indicated for patients who have received at least one prior therapy. ... One of these is Darzalex, another drug for multiple myeloma that is indicated across all lines of therapy.
-
Why we need to improve diverse representation in clinical trials
Since 20% of all U.S. multiple myeloma patients are from this 12% of the population, the current ratio is, quite frankly, ridiculous.
-
Life with multiple myeloma - why I'm a lucky man living the dream
The second treatment also failed to dent the myeloma and left me with permanent numbness in my feet. ... Apart from losing my hair, I felt relatively unscathed, unfortunately so did the myeloma, in fact my biomarkers went up.
-
Highlights in haematologic malignancy from ASH 2018
Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 2 fully matching, plus 10 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
